Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2022
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet this
Print
Michael Dudley, n/a
CEO
Qpex Biopharma
Disclosure(s): ArrePath: Board Member; Qpex Biopharma: Board Member, Employee
Poster(s):
216 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects
Thursday, October 20, 2022
12:15 PM – 1:30 PM
US ET
217 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Lipopeptide QPX9003 in Healthy Adult Subjects
Thursday, October 20, 2022
12:15 PM – 1:30 PM
US ET
218 - A Phase 1 Study of the Single-Dose Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor Xeruborbactam Administered as the Isobutyryloxymethyl Oral Prodrug to Healthy Adult Subjects
Thursday, October 20, 2022
12:15 PM – 1:30 PM
US ET
.png)
.png)